Skip to content

US · DARE · BIOTECHNOLOGY

Dare Bioscience, Inc. (DARE) intrinsic value and stock valuation

$0.41as of 2026-11-21 · Mkt cap 12.76M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Dare Bioscience, Inc. DCF and intrinsic value

InvestorsCraft values DARE with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from DARE’s statements →

Dare Bioscience, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Diego, CA 92122 darebioscience.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$1.03M
20112025
Net income
-$-13.4M
20112025
Free cash flow
-$-10.27M
20112025
Total equity
$2.84M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$1.03M$10K$2.81M$10M$0.00
Operating income-$-13.55M-$-23.45M-$-30.94M-$-31.39M-$-39.07M
Net income-$-13.4M-$-4.05M-$-30.16M-$-30.95M-$-38.7M
EPSd-$-119.87K-$-476.47K-$-4.14M-$-4.39M-$-7.59M
Operating cash flow-$-9.89M$5.39M-$-38.86M-$-18.09M-$-28.76M
Capital expenditure-$-390K-$-570K-$-630K-$-60K-$-10K
Free cash flow-$-10.27M$4.82M-$-39.49M-$-18.15M-$-28.78M
Total assets$32.5M$22.1M$21.3M$43.8M$55.8M
Total debt$2.66M$1.3M$1.4M$490K$270K
Net debt-$-22.06M-$-14.4M-$-9.07M-$-34.18M-$-51.4M
Total equity$2.84M-$-6.01M-$-5.05M$11.1M$38.8M
Cash and short-term investments$24.7M$15.7M$10.5M$34.7M$51.7M
Income statement
20252024202320222021
Revenue$1.03M$10K$2.81M$10M$0.00
Cost of revenue$2.45M$14.3M$21.6M$30.1M$100K
Gross profit-$-1.42M-$-14.3M-$-18.83M-$-20.14M-$-100K
Research and development expenses$5.52B$14.2M$21.5M$30M$30.6M
Selling, general and administrative expenses$8.76M$9.16M$11.9M$11.2M$8.35M
Other expenses-$-5.52B-$-14.21M-$-21.34M-$-30.04M$0.00
Operating expenses$12.1M$9.16M$12.1M$11.2M$39M
Cost and expenses$14.6M$23.5M$33.8M$41.4M$39.1M
Interest income$680K$0.00$0.00$0.00$0.00
Interest expense$820K$0.00$0.00$0.00$0.00
Depreciation and amortization$2.15M$40K$40K$20K$30K
Ebitda-$-10.43M-$-4.01M-$-30.7M-$-30.92M-$-38.67M
Operating income-$-13.55M-$-23.45M-$-30.94M-$-31.39M-$-39.07M
Total other income/expenses, net$150K$19.4M$780K$440K$370K
Income before tax-$-13.4M-$-4.05M-$-30.16M-$-30.95M-$-38.7M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-13.4M-$-4.05M-$-30.16M-$-30.95M-$-38.7M
Weighted average shares outstanding$111.8M$8.5M$7.28M$7.05M$5.1M
Weighted average diluted shares outstanding$111.8M$8.5M$7.28M$7.05M$5.1M
Balance sheet
20252024202320222021
Cash and short-term investments$24.7M$15.7M$10.5M$34.7M$51.7M
Net receivables$570K$230K$950K$1.7M$1.15M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$27.1M$18.5M$17.5M$43M$55.3M
Property, plant and equipment, net$4.4M$2.54M$1.98M$520K$240K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$340K$0.00$0.00
Total non-current assets$5.41M$3.65M$3.74M$790K$510K
Total assets$32.5M$22.1M$21.3M$43.8M$55.8M
Accounts payable$1.2M$1.46M$3.39M$2.03M$2.1M
Short-term debt$2.1M$550K$470K$400K$270K
Deferred revenue$19.7M$16.6M$13.7M$18.3M$10.5M
Total current liabilities$23.7M$21.6M$20.5M$31.6M$16.1M
Long-term debt$560K$750K$940K$90K$0.00
Deferred revenue, non-current$0.00$1M$1M$1M$1M
Total non-current liabilities$5.95M$6.5M$5.85M$1.09M$1M
Capital lease obligations$2.66M$1.3M$1.4M$490K$270K
Total liabilities$29.6M$28.1M$26.3M$32.7M$17.1M
Common stock$0.00$0.00$10K$10K$10K
Retained earnings-$-188.69M-$-175.29M-$-171.24M-$-141.07M-$-110.13M
Accumulated other comprehensive income (loss)-$-420K-$-430K-$-360K-$-350K-$-150K
Total equity$2.84M-$-6.01M-$-5.05M$11.1M$38.8M
Total investments$0.00$0.00$340K$0.00$0.00
Total debt$2.66M$1.3M$1.4M$490K$270K
Net debt-$-22.06M-$-14.4M-$-9.07M-$-34.18M-$-51.4M
Cash flow statement
20252024202320222021
Net income-$-13.4M-$-4.05M-$-30.16M-$-30.95M-$-38.7M
Depreciation and amortization$2.15M$40K$40K$20K$30K
Stock-based compensation$1.5M$2.2M$2.53M$2.16M$1.6M
Change in working capital-$-210K$5.81M-$-10.43M$10.7M$8.73M
Accounts receivable-$-340K$720K$750K-$-560K-$-690K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-260K-$-1.93M$1.36M-$-80K$1.08M
Net cash provided by operating activities-$-9.89M$5.39M-$-38.86M-$-18.09M-$-28.76M
Investments in property, plant and equipment-$-390K-$-570K-$-630K-$-60K-$-10K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-390K-$-570K-$-630K-$-60K-$-10K
Common stock issued$20.9M$450K$9.35M$1.22M$75.3M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$19.3M$430K$15.6M$1.34M$75.9M
Net change in cash$9.01M$5.19M-$-23.86M-$-17M$47M
Cash at end of period$25M$16M$10.8M$34.7M$51.7M
Operating cash flow-$-9.89M$5.39M-$-38.86M-$-18.09M-$-28.76M
Capital expenditure-$-390K-$-570K-$-630K-$-60K-$-10K
Free cash flow-$-10.27M$4.82M-$-39.49M-$-18.15M-$-28.78M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Dare Bioscience, Inc.

        Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.

        CEO
        Sabrina Martucci Johnson
        Employees
        24
        Beta
        1.02

        Explore

        Frequently asked questions

        What is the intrinsic value of Dare Bioscience, Inc. (DARE)?

        InvestorsCraft does not currently publish an intrinsic value for DARE. How the IC value is calculated.

        Is DARE undervalued?

        InvestorsCraft does not publish an undervaluation signal for DARE at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.